Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jan Serroyen

Showing results (31-40 of 45) with videos related to

Pageof 5
Sort By:
NPJ Vaccines|November 25, 2024
Ad26.RSV.preF completely protects calves from severe respiratory disease induced by bovine RSV challengeLeslie van der Fits, Rineke de Jong, Karin Dijkman, et al.
Clinical & Translational Immunology|April 22, 2026
An Ad26-MVA-BN-based therapeutic vaccine targeting HPV16 and HPV18 related disease is immunogenic in preclinical models and in women with persistent HPV infectionsSelina Khan, Satish Boedhoe, Miranda Baert, et al.
Vaccines|December 23, 2023
Intravenous Administration of Ad26.COV2.S Does Not Induce Thrombocytopenia or Thrombotic Events or Affect SARS-CoV-2 Spike Protein Bioavailability in Blood Compared with Intramuscular Vaccination in RabbitsSelina Khan, Sonia Marquez-Martinez, Tim Erkens, et al.
International Journal of Cancer|March 7, 2017
Development of a replication-deficient adenoviral vector-based vaccine candidate for the interception of HPV16- and HPV18-induced infections and diseaseSelina Khan, Koen Oosterhuis, Kerstin Wunderlich, et al.
Vaccine|January 2, 2022
Immunogenicity and protective efficacy of adenoviral and subunit RSV vaccines based on stabilized prefusion F protein in pre-clinical modelsEirikur Saeland, Leslie van der Fits, Renske Bolder, et al.
Vaccine|July 11, 2016
Immunogenicity and safety of a tetravalent E. coli O-antigen bioconjugate vaccine in animal modelsGermie P J M van den Dobbelsteen, Kellen C Faé, Jan Serroyen, et al.
Vaccine|November 28, 2018
Increasing FIM2/3 antigen-content improves efficacy of Bordetella pertussis vaccines in mice in vivo without altering vaccine-induced human reactogenicity biomarkers in vitroAnne Marie Queenan, David J Dowling, Wing Ki Cheng, et al.
Human Gene Therapy|August 18, 2017
Adenoviral Type 35 and 26 Vectors with a Bidirectional Expression Cassette in the E1 Region Show an Improved Genetic Stability Profile and Potent Transgene-Specific Immune ResponseMarija Vujadinovic, Kerstin Wunderlich, Benoit Callendret, et al.
NPJ Vaccines|March 23, 2023
Combination Ad26.RSV.preF/preF protein vaccine induces superior protective immunity compared with individual vaccine components in preclinical modelsEirikur Saeland, Leslie van der Fits, Renske Bolder, et al.
Vaccines|May 25, 2024
The Biodistribution of the Spike Protein after Ad26.COV2.S Vaccination Is Unlikely to Play a Role in Vaccine-Induced Immune Thrombotic ThrombocytopeniaSonia Marquez-Martinez, Selina Khan, Joan van der Lubbe, et al.
Pageof 5

Showing results (31-40 of 45) with videos related to

Sort By:
Pageof 5
NPJ Vaccines|November 25, 2024
Ad26.RSV.preF completely protects calves from severe respiratory disease induced by bovine RSV challengeLeslie van der Fits, Rineke de Jong, Karin Dijkman, et al.
Clinical & Translational Immunology|April 22, 2026
An Ad26-MVA-BN-based therapeutic vaccine targeting HPV16 and HPV18 related disease is immunogenic in preclinical models and in women with persistent HPV infectionsSelina Khan, Satish Boedhoe, Miranda Baert, et al.
Vaccines|December 23, 2023
Intravenous Administration of Ad26.COV2.S Does Not Induce Thrombocytopenia or Thrombotic Events or Affect SARS-CoV-2 Spike Protein Bioavailability in Blood Compared with Intramuscular Vaccination in RabbitsSelina Khan, Sonia Marquez-Martinez, Tim Erkens, et al.
International Journal of Cancer|March 7, 2017
Development of a replication-deficient adenoviral vector-based vaccine candidate for the interception of HPV16- and HPV18-induced infections and diseaseSelina Khan, Koen Oosterhuis, Kerstin Wunderlich, et al.
Vaccine|January 2, 2022
Immunogenicity and protective efficacy of adenoviral and subunit RSV vaccines based on stabilized prefusion F protein in pre-clinical modelsEirikur Saeland, Leslie van der Fits, Renske Bolder, et al.
Vaccine|July 11, 2016
Immunogenicity and safety of a tetravalent E. coli O-antigen bioconjugate vaccine in animal modelsGermie P J M van den Dobbelsteen, Kellen C Faé, Jan Serroyen, et al.
Vaccine|November 28, 2018
Increasing FIM2/3 antigen-content improves efficacy of Bordetella pertussis vaccines in mice in vivo without altering vaccine-induced human reactogenicity biomarkers in vitroAnne Marie Queenan, David J Dowling, Wing Ki Cheng, et al.
Human Gene Therapy|August 18, 2017
Adenoviral Type 35 and 26 Vectors with a Bidirectional Expression Cassette in the E1 Region Show an Improved Genetic Stability Profile and Potent Transgene-Specific Immune ResponseMarija Vujadinovic, Kerstin Wunderlich, Benoit Callendret, et al.
NPJ Vaccines|March 23, 2023
Combination Ad26.RSV.preF/preF protein vaccine induces superior protective immunity compared with individual vaccine components in preclinical modelsEirikur Saeland, Leslie van der Fits, Renske Bolder, et al.
Vaccines|May 25, 2024
The Biodistribution of the Spike Protein after Ad26.COV2.S Vaccination Is Unlikely to Play a Role in Vaccine-Induced Immune Thrombotic ThrombocytopeniaSonia Marquez-Martinez, Selina Khan, Joan van der Lubbe, et al.
Pageof 5